NOPAIN for Veterans Act
- Sponsor
- Rep. Landsman, Greg [D-OH-1]
- Committees
- Veterans' Affairs Committee (primary)
- Last action
- Jan 13, 2026
Bottom line
The bill aims to expand veterans' access to non-opioid pain management options within the VA healthcare system, potentially reducing reliance on opioids.
What it actually does
This bill mandates that the Department of Veterans Affairs (VA) include certain non-opioid pain management drugs and biological products in its national formulary and drug standardization list. These products must be approved by the Food and Drug Administration (FDA) for postoperative pain or regional analgesia without acting on opioid receptors. The VA must implement these changes within 90 days of enactment, and include eligible drugs within one year of their eligibility for specific temporary additional or separate payments under the Social Security Act or Code of Federal Regulations.
Proponents argue
Supporters argue that this bill will enhance the quality of care for veterans by ensuring access to a broader range of pain management options, specifically non-opioid alternatives. This is seen as a crucial step in combating the opioid crisis among veterans and providing safer, effective treatments for pain without the risk of addiction associated with opioids.
Opponents contend
Critics might contend that mandating specific drug categories for inclusion in the VA's national formulary could limit the VA's flexibility in managing its drug procurement and formulary decisions. They may also raise concerns about potential increased costs or the administrative burden of integrating these products, especially if the VA's clinical judgment suggests other alternatives are more appropriate or cost-effective for certain patient populations.
The bill is very short and clear, allowing ample time for any interested reader to understand its provisions thoroughly.
Section 2(a), amending 38 U.S.C. 8125
Mandatory Inclusion of Non-Opioid Pain Medications in VA Formulary
This provision requires the Secretary of Veterans Affairs to include specific non-opioid pain management drugs and biological products in the Department's national formulary and drug standardization list. These products must be FDA-approved for reducing postoperative pain or producing postsurgical/regional analgesia without targeting opioid receptors. The VA must add these drugs within one year of them becoming eligible for temporary additional payments under Medicare or separate payments under specific federal regulations.
Supporters argue
Proponents argue that this provision is essential for modernizing pain management within the VA, offering veterans safer and more diverse treatment pathways. It directly addresses the need to reduce opioid prescriptions by ensuring readily available alternatives, thereby improving veteran health outcomes and quality of life.
Critics contend
Opponents might argue that such a mandate could reduce the VA's clinical autonomy and flexibility to make formulary decisions based on the most current evidence, cost-effectiveness, or specific patient population needs. They may also suggest that a broad mandate could inadvertently prioritize certain drugs over others that might be more suitable in specific clinical contexts.
Tradeoffs
This provision balances the goal of ensuring access to specific non-opioid treatments with the VA's need for flexibility in managing its formulary. It also navigates the tension between potentially higher costs associated with mandated inclusions and the long-term benefits of reducing opioid dependence and its associated societal costs.
This subsection explicitly prohibits the use of funds from the Cost of War Toxic Exposures Fund (established under section 324 of title 38, United States Code) to carry out the amendments made by this Act.
Section 2(b)
Why it matters:This exclusion is likely a deliberate legislative choice to protect the integrity and dedicated purpose of the Toxic Exposures Fund, ensuring its resources remain solely for veterans affected by toxic exposures. It may also be a strategic move to garner broader support by addressing concerns about potential fund diversion.
Case for: Supporters argue this ensures that the critical funds dedicated to veterans suffering from toxic exposures are not diluted or diverted for other, albeit important, VA initiatives. It maintains the specific legislative intent behind the Toxic Exposures Fund.
Case against: Critics might argue that by excluding a potentially significant funding source, the bill places a greater burden on other VA appropriations, which could lead to funding shortfalls elsewhere or delay the implementation of the non-opioid pain management program if alternative funds are scarce.
Estimated impact: Prevents a specific, large fund from being used, thereby requiring the VA to identify alternative funding sources from its general appropriations for the implementation of the non-opioid formulary expansion.